Literature DB >> 22472992

Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians.

E Comets1, B Diquet, S Legrain, M-G Huisse, A Godon, C Bruhat, M-P Chauveheid, S Delpierre, X Duval, G Berrut, C Verstuyft, M-C Aumont, F Mentré.   

Abstract

In the PREPA observational study, we investigated the factors influencing pharmacokinetic and pharmacodynamic variability in the responses to fluindione, an oral anticoagulant drug, in a general population of octogenarian inpatients.Measurements of fluindione concentrations and international normalized ratio (INR ) were obtained for 131 inpatients in whom fluindione treatment was initiated. Treatment was adjusted according to routine clinical practice. The data were analyzed using nonlinear mixed-effects modeling, and the parameters were estimated using MONOLI X 3.2. The pharmacokinetics (PK) of fluindione was monocompartmental, whereas the evolution of INR was modeled in accordance with a turnover model (inhibition of vitamin K recycling). Interindividual variability (II V) was very large. Clearance decreased with age and with prior administration of cordarone. Patients who had undergone surgery before the study had lower IC50 values, leading to an increased sensitivity to fluindione. Pharmacokinetic exposure is substantially increased in elderly patients, warranting a lower dose of fluindione.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22472992      PMCID: PMC3789273          DOI: 10.1038/clpt.2011.309

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  46 in total

1.  Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).

Authors:  Jack Ansell; Jennifer Hollowell; Vittorio Pengo; Fernando Martinez-Brotons; Jaime Caro; Ludovic Drouet
Journal:  J Thromb Thrombolysis       Date:  2007-04       Impact factor: 2.300

2.  Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology.

Authors:  Alec Vahanian; Helmut Baumgartner; Jeroen Bax; Eric Butchart; Robert Dion; Gerasimos Filippatos; Frank Flachskampf; Roger Hall; Bernard Iung; Jaroslaw Kasprzak; Patrick Nataf; Pilar Tornos; Lucia Torracca; Arnold Wenink
Journal:  Eur Heart J       Date:  2007-01-26       Impact factor: 29.983

Review 3.  Hemorrhagic complications of anticoagulant treatment.

Authors:  M N Levine; G Raskob; S Landefeld; C Kearon
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

4.  Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients.

Authors:  F Mentré; F Pousset; E Comets; B Plaud; B Diquet; G Montalescot; A Ankri; A Mallet; P Lechat
Journal:  Clin Pharmacol Ther       Date:  1998-01       Impact factor: 6.875

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Prediction of fluindione maintenance dosage hampered by large intraindividual variability.

Authors:  E Comets; F Pousset; F Mentré; B Diquet; A Ankri; A Mallet; P Lechat
Journal:  Ther Drug Monit       Date:  2000-12       Impact factor: 3.681

Review 7.  Systematic overview of warfarin and its drug and food interactions.

Authors:  Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells
Journal:  Arch Intern Med       Date:  2005-05-23

8.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Clive Kearon; Susan R Kahn; Giancarlo Agnelli; Samuel Goldhaber; Gary E Raskob; Anthony J Comerota
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors:  Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

10.  [Prospective study of oral anticoagulation control in 110 very elderly hospitalized patients and of risk factors for poor control].

Authors:  Thomas Vogel; Virginie Coriol; Georges Kaltenbach; Michèle Kiesmann; Marc Berthel
Journal:  Presse Med       Date:  2008-07-17       Impact factor: 1.228

View more
  4 in total

1.  Assessment of the Impact of L-Thyroxine Therapy on Bleeding Risk in Patients Receiving Vitamin K Antagonists.

Authors:  Farès Moustafa; Rémi Malhomme; Bruno Pereira; Alain Barres; Jennifer Saint-Denis; Frederic Dutheil; Marie Batisse; Jeannot Schmidt
Journal:  Clin Drug Investig       Date:  2017-10       Impact factor: 2.859

2.  Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG).

Authors:  Matthieu Plichart; Gilles Berrut; Nathalie Maubourguet; Claude Jeandel; Jean-Paul Emeriau; Joël Ankri; Hélène Bouvier; Geneviève Ruault; Olivier Hanon
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

Review 3.  Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.

Authors:  Virginie Siguret; Isabelle Gouin-Thibault; Pascale Gaussem; Eric Pautas
Journal:  Drugs Aging       Date:  2013-09       Impact factor: 3.923

4.  Polypharmacy in the elderly from the clinical toxicologist perspective.

Authors:  H J Heppner; M Christ; M Gosch; W Mühlberg; P Bahrmann; T Bertsch; C Sieber; K Singler
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.